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The leukaemias are a biologically and clinically diverse group of
malignancies originating from precursors of the various blood
cell series. Advances in basic science and cell surface markers in
the last 20 years have led to revised clinical classifications of the
leukaemias, as with the lymphomas (Percy et al., 1984), but these
advances were not all reflected in the first two editions of the
International Classification of Diseases for Oncology (ICD-O)
(Percy et al, 1990; World Health Organisation, 1976), used by
cancer registries world-wide to encode the morphology of
neoplasms for robust international comparisons. The third
edition of ICD-O incorporates these changes, but was introduced
too recently to affect these data (Fritz et al, 2000). As a result,
population-based data series from cancer registries cannot always
be used to address clinical questions about trends in outcome for
recently defined disease subgroups, as systematic realignment of
older data to the more specific recent categories may be
impossible. Acute and chronic myeloid leukaemia, chronic
lymphoid leukaemia (CLL) and monocytic leukaemia account for
90% of leukaemias in adults in England and Wales. Acute
lymphocytic leukaemia is mainly a disease of childhood. Informa-
tion on survival for all adult leukaemias combined remains of
some interest; however, even though the results are a weighted
average of socioeconomic patterns and trends in survival for the
different types of leukaemia.
Approximately 6200 adults are diagnosed with a leukaemia each
year in England and Wales, some 3% of all malignancies. Incidence
is marginally higher among more affluent groups, and approxi-
mately 30% higher in men overall, but the male excess is more
marked for CLL. Incidence has been increasing only slowly since
the 1970s, mostly among the elderly (Quinn et al., 2001).
Geographic variation in incidence has not been marked.
Benzene and ionising radiation are well-established causes of
leukaemia, although organic solvents, some viruses (IARC, 1996;
Lynge et al., 1997; Stellman, 1998) and some antineoplastic drugs
are also leukaemogenic (Kaldor et al., 1990). Nevertheless, all these
potential causes explain only a small proportion of incident cases.
Of nearly 73000 patients registered with a leukaemia in England
and Wales during the period 1986–1999, only approximately
57000 (78.3%) could be included in survival analyses. As many as
16% of patients were excluded from analysis because their dates of
diagnosis and death were identical: this proportion was exceeded
only for tumours of the lung and pancreas (Coleman et al., 2004).
In these data, it was not possible to distinguish patients who died
on the day of diagnosis (true zero survival) from those whose date
of diagnosis was simply unknown, because they were registered
from a death certificate only (DCO), but it is likely that the great
majority of such cases were DCOs. The vital status of another 2%
of patients was unknown on 5 November 2002, when the data were
extracted for analysis, and leukaemia was not the first primary
malignancy for a further 3.5% of patients; both groups were also
excluded from analysis.
After a steady long-term increase, the incidence of leukaemia in
England and Wales reached a plateau in the early 1990s at
approximately 10 per 100000 per year in men and 7.5 in women.
The rise in incidence was less steep among more deprived groups,
leading to lower incidence than among the more affluent groups of
the population, particularly for men.
SURVIVAL TRENDS
For leukaemia patients diagnosed at the end of the 1990s, relative
survival at 1 year was approximately 60%, whereas 5-year survival
was 36% (women) or 40% (men; Table 1). Among men, 5-year
survival increased significantly by approximately 5% every 5 years
between 1986 and 1999, after adjustment for changes in the
distribution of incident cases by deprivation category (Figure 1).
For women, increases in survival since the late 1980s have been
smaller and the pace of increase in survival every 5 years was not
statistically significant. Survival among women is generally lower
than for men, although 10-year survival is similar in the two sexes.
Hybrid analysis of the survival probabilities observed during
2000–2001 (Brenner and Rachet, 2004) reflects the continuing
increase, but even for patients diagnosed around that time, relative
survival at 5 and 10 years will still only reach approximately 40 and
30%, respectively.
DEPRIVATION
The deprivation gap in survival from leukaemia in adults is
consistently and significantly in favour of the more affluent groups
(Table 2, Figure 2). The fitted difference between the most affluent
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least 5%, with slightly smaller differences in 10-year survival. For
adults diagnosed with leukaemia during the late 1990s, 1-year
survival was approximately 6% higher for the most affluent fifth of
the adult population than for the most deprived fifth, in both
sexes, with 5-year survival 3–4% higher.
For the cohort of men diagnosed with leukaemia during the
early 1990s, the deprivation gap in survival at 1, 5 and 10 years
after diagnosis seemed substantially wider than for men
diagnosed in the late 1980s, but over the whole 14-year period
1986–1999, no consistent change in the deprivation gradient
occurred. Among women, there is some evidence of shrinkage
of the deprivation gradient in survival, particularly at 5 years
(Table 2).
Short-term predictions based on hybrid analysis to predict the
likely socioeconomic differences in survival for patients diagnosed
during 2000–2001 do not suggest any imminent reduction in the
deprivation gap (Table 2).
Table 1 Trends in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults (15–99 years) diagnosed
during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
Survival
(%) 95% CI
1 year Men 56.7 (55.6, 57.7) 60.0 (59.1, 60.9) 61.9 (60.9, 62.9) 2.9** (1.0, 4.9) 61.3 (59.8, 62.7)
Women 52.8 (51.7, 53.9) 55.6 (54.5, 56.6) 57.3 (56.1, 58.4) 1.5 ( 0.7, 3.7) 56.2 (54.6, 57.9)
5 years Men 30.7 (29.6, 31.7) 35.3 (34.3, 36.3) 39.7 (38.4, 41.0) 4.7** (2.4, 7.0) 39.4 (37.8, 41.0)
Women 30.0 (28.9, 31.1) 34.5 (33.3, 35.6) 35.9 (34.4, 37.3) 1.7 ( 0.8, 4.2) 35.4 (33.7, 37.1)
10 years Men 21.1 (20.1, 22.1) 25.8 (24.6, 27.0) 8.4** (4.4, 12.5) 29.5 (27.8, 31.2)
Women 21.8 (20.7, 22.9) 27.3 (26.0, 28.6) 5.2* (0.8, 9.7) 28.6 (26.8, 30.4)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in survival every 5 years, adjusted for
deprivation (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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Figure 1 Relative survival (%) up to 10 years after diagnosis by sex and
calendar period of diagnosis: England and Wales, adults (15-99 years)
diagnosed during 1986–1999 and followed up to 2001. Survival estimated
with cohort or complete approach (1986–1990, 1991–1995, 1996–
1999) or hybrid approach (2000–2001) (see Rachet et al, 2008).
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Figure 2 Trends in the deprivation gap in 5-year relative survival (%) by
sex and calendar period of diagnosis: England and Wales, adults (15–99
years) diagnosed during 1986–1999 and followed up to 2001.
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The main limitation of these analyses is that population-based
survival trends could not be produced for the specific subtypes of
leukaemia defined by recent clinical classifications, although
overall survival trends among adults have been broadly similar
for all the main types of leukaemia (Berrino et al., 1995, 1999, 2003;
Coleman et al., 1999, 2004).
Despite therapeutic progress, however, the trends and socio-
economic patterns in survival from leukaemia in adults provide a
striking contrast with those for leukaemia in children.
Survival from all leukaemias combined in adults has improved
steadily, but not rapidly, reaching approximately 40% 5-year
survival for adults diagnosed by the end of the 1990s, and the
deprivation gradient in survival is marked and persistent for both
men and women.
For children with leukaemia, in contrast, the increase in survival
since the 1970s has been dramatic, 5-year survival reaching
80% by the end of the 1990s. Furthermore, there is no significant
socioeconomic gradient in survival, whether for all the leukaemias
combined or for acute lymphoblastic leukaemia in particular
(Stiller and Eatock, 1994; Coleman et al., 1999; Schillinger et al.,
1999).
The disparities in the trends and socioeconomic inequalities in
survival from leukaemia between children and adults are remark-
able, and they merit further exploration.
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Table 2 Trends in the deprivation gap in relative survival (%) by sex, time since diagnosis and calendar period of diagnosis: England and Wales, adults
(15–99 years) diagnosed during 1986–1999 and followed up to 2001
Calendar period of diagnosis
a
Average change (%) Prediction
c for patients
1986–1990 1991–1995 1996–1999 every 5 years
b diagnosed during 2000–2001
Time since
diagnosis
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
Deprivation
gap (%) 95% CI
1 year Men  5.7** ( 8.7,  2.8)  9.5** ( 12.2,  6.8)  6.0** ( 9.0,  3.1)  0.2 ( 2.4, 2.0)  6.0** ( 10.2,  1.9)
Women  7.8** ( 11.2,  4.5)  6.4** ( 9.5,  3.3)  5.8** ( 9.1,  2.5) 1.1 ( 1.4, 3.6)  9.2** ( 13.9,  4.5)
5 years Men  5.5** ( 8.6,  2.5)  9.6** ( 12.5,  6.7)  4.4* ( 8.3,  0.5) 0.0 ( 2.5, 2.6)  3.8 ( 8.3, 0.8)
Women  6.1** ( 9.4,  2.8)  4.9** ( 8.1,  1.7)  2.5 ( 6.7, 1.6) 1.8 ( 0.9, 4.6)  4.8 ( 9.7, 0.2)
10 years Men  2.3 ( 5.3, 0.7)  7.2** ( 10.7,  3.8)  4.9* ( 9.5,  0.3)  2.4 ( 7.1, 2.4)
Women  3.7* ( 6.9,  0.4)  3.3 ( 7.1, 0.4) 0.3 ( 4.7, 5.3)  3.3 ( 8.5, 1.9)
CI¼confidence interval.
aSurvival estimated with cohort or complete approach (see Rachet et al, 2008).
bMean absolute change (%) in the deprivation gap in survival every
5 years, adjusted for the underlying trend in survival (see Rachet et al, 2008).
cSurvival estimated with hybrid approach (see Rachet et al, 2008). *Po0.05; **Po0.01.
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